Every Form 4 that Talphera, Inc. (TLPH) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TLPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TLPH filings page.
TALPHERA, INC. director Mark A. Wan reported equity awards that increase his direct stake in the company. He received 5,100 shares of common stock as a grant, bringing his direct holdings to 13,959 shares. He was also granted options to buy 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. The filing notes that the 5,100 restricted stock units and all of the option shares vest in full on the first anniversary of the grant date, as long as he continues to provide service to TALPHERA.
TALPHERA, INC. director Joseph Todisco reported equity awards under the company’s compensation program. He acquired 5,100 shares of common stock at no cost, bringing his direct holdings to 11,497 shares after the transaction.
He was also granted a director stock option covering 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. According to the footnotes, 100% of these stock units and option shares vest on the first anniversary of the June 22, 2026 grant date, subject to his continuous service to the company.
TALPHERA, INC. director Abhinav Jain reported equity compensation grants consisting of restricted stock units and stock options. He received 5,100 shares of common stock as a grant, bringing his direct holdings to 12,412 shares after the transaction. These awards carry no cash purchase price.
On the same date, he was granted stock options for 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. Footnotes state that 100% of the restricted stock units and 100% of the option shares vest on the first anniversary of the grant date, subject to his continuous service to the company.
TALPHERA, INC. director Stephen J. Hoffman received new equity awards as part of his compensation. On June 22, 2026, he was granted 5,100 shares of common stock at no cost, increasing his direct common stock holdings to 13,959 shares after the award.
He also received a stock option for 30,700 shares of common stock with an exercise price of $0.98 per share, expiring on June 21, 2036. Footnotes state that all 5,100 restricted stock units and all 30,700 option shares will vest in full on the first anniversary of the grant date, provided he continues to serve the company.
TALPHERA, INC. director Jill Marie Broadfoot reported equity awards consisting of restricted stock units and stock options. She received 5,100 shares of common stock as a grant at no cost and now holds 13,647 common shares directly. She was also granted options on 30,700 shares at an exercise price of $0.98 per share, expiring in 2036. Both the restricted stock units and the option grant vest in full on the first anniversary of the grant date, contingent on her continuous service with the company.
TALPHERA, INC. director Marina Bozilenko received equity compensation in the form of restricted stock units and stock options. She was granted 5,100 restricted stock units, each representing one share of common stock, all vesting on the first anniversary of the grant date, subject to her continuous service.
She was also granted options to purchase 30,700 shares of common stock at an exercise price of $0.98 per share, with 100% of the option shares vesting on the one-year anniversary of the grant date, also contingent on continued service. Following these awards, she directly holds 14,147 shares of common stock and 30,700 options.
TALPHERA, INC. director Adrian Adams received new equity awards. On June 22, 2026, he was granted 5,100 restricted stock units, each representing the right to receive one share of common stock. These RSUs vest 100% on the first anniversary of the grant, if he remains in continuous service.
Adams also received a stock option for 30,700 shares of common stock at an exercise price of $0.98 per share, expiring on June 21, 2036. The option vests in full one year after the grant date, subject to his continued service, and brings his direct common stock holdings to 22,709 shares after the RSU grant.
TALPHERA, INC. Chief Medical Officer Shakil Aslam reported a routine tax-related share disposition. On May 20, 2026, 4,518 shares of common stock were surrendered to the company to cover required tax withholdings tied to the vesting of restricted stock units. After this non-market transaction, Aslam directly holds 76,542 shares of TALPHERA common stock.
TALPHERA, INC. CEO Vincent J. Angotti reported a routine tax-related share disposition. On April 2, 2026, he surrendered 9,938 shares of common stock at $0.7223 per share to the company to cover required tax withholdings from vesting RSUs. After this transaction, he directly holds 790,767 shares of TALPHERA common stock.
TALPHERA, INC. Chief Financial Officer Raffi Asadorian reported a routine share disposition related to taxes. On the RSU vesting date, 2,444 shares of common stock were surrendered back to the company at $0.7223 per share to cover required tax withholdings, rather than being sold on the open market. Following this tax-withholding transaction, the CFO directly holds 85,879 shares of Talphera common stock.
TALPHERA, INC. Chief Medical Officer Aslam Shakil reported a tax-withholding share disposition related to vesting restricted stock units. On this Form 4, 2,118 shares of common stock were surrendered back to the company at an effective price of $0.7223 per share to cover required tax withholdings. After this transaction, Shakil directly holds 81,060 shares of TALPHERA common stock. The filing records a compensation-related tax event rather than an open-market purchase or sale.
TALPHERA, INC. Chief Engineering Officer Badri N. Dasu reported a routine tax-related share disposition. On the RSU vesting date, 2,444 shares of common stock were surrendered back to the company at an implied price of $0.7223 per share to cover required tax withholdings, rather than being sold on the open market. After this withholding transaction, Dasu directly holds 71,440 shares of TALPHERA common stock.
TALPHERA, INC. Chief Executive Officer Vincent J. Angotti purchased 213,310 shares of common stock in an open-market transaction at $0.586 per share. Following this purchase, he directly owns 800,705 common shares. Footnotes note these shares relate to the third tranche closing of a PIPE financing and that the balance includes 10,000 shares acquired through the company’s employee stock purchase plan.
Nantahala Capital Management-linked funds acquired 4,266,211 pre-funded warrants to purchase Talphera common stock at $0.585 per warrant, with an exercise price of $0.001 per share. These warrants are exercisable indefinitely, bringing the reporting group’s total to 18,822,267 warrants held indirectly. Nantahala, Wilmot B. Harkey, and Daniel Mack may be deemed beneficial owners but each disclaims ownership beyond their pecuniary interest.
Talphera, Inc. chief executive officer Vincent J. Angotti reported several equity transactions in company stock. On February 12, 2026, he made an open-market purchase of 105,364 shares of common stock at $0.8123 per share, increasing his direct ownership.
That same day, he received a grant of stock options for 594,000 shares, which vest over four years, with one quarter vesting on the one-year anniversary of the grant and the remainder vesting in 36 monthly installments. On February 10 and 14, 2026, a total of 12,738 shares of common stock were surrendered to cover tax withholdings tied to restricted stock unit vesting. After the February 14 tax-withholding disposition, his direct common stock holdings were 577,395 shares, which include a non-reportable acquisition of 10,000 shares through the company’s employee stock purchase plan.
TALPHERA, INC. Chief Medical Officer Aslam Shakil reported two insider transactions. He was granted a stock option covering 205,000 shares of common stock at an exercise price of $0.0000 per share. One fourth of this option vests on the one-year anniversary of the February 12, 2026 grant date, with the remaining shares vesting in 36 equal monthly installments, subject to continued service. On the same date, he also purchased 35,000 shares of common stock in the open market at $0.8123 per share, bringing his direct common stock holdings to 83,178 shares and his option holdings to 205,000 shares.
TALPHERA, INC. Chief Engineering Officer Badri N Dasu reported multiple equity transactions. On February 12, 2026, he purchased 35,000 shares of common stock at $0.8123 per share in an open-market transaction and received a stock option for 200,000 shares of common stock. The option was granted at an exercise price of $0.0000 and will vest over four years, with one quarter vesting on the one-year anniversary of the grant and the remainder vesting in 36 equal monthly installments.
On February 10 and 14, 2026, a total of 3,127 shares of common stock were surrendered in tax-withholding dispositions related to vesting restricted stock units, as noted in the footnote describing shares surrendered to cover required tax withholdings. Following these transactions, Badri N Dasu directly owned 73,884 shares of common stock in one of the reported positions, reflecting his ongoing equity stake in the company.
TALPHERA, INC. Chief Financial Officer Raffi Asadorian reported multiple equity transactions in company stock. He purchased 45,000 shares of common stock in an open-market transaction at $0.8123 per share and now holds a larger direct share position.
He was also granted a stock option for 260,000 shares of common stock, with one quarter vesting on the one-year anniversary of the February 12, 2026 grant and the rest vesting monthly over three years while he remains in service. In separate moves tied to restricted stock unit vesting, he surrendered 2,933 shares and 958 shares of common stock to cover required tax withholdings, leaving 88,323 shares directly owned after the latest tax-related disposition.
Talphera (TLPH) disclosed a director equity grant on Form 4. On 10/23/2025, the reporting person received 4,267 restricted stock units, each representing one share of common stock. The RSUs vest 100% on the first anniversary of the grant date, contingent on continuous service.
On the same date, the director was granted a stock option for 25,600 shares at an exercise price of $1.14, expiring on 10/22/2035, with 100% vesting after one year. Following these transactions, the director beneficially owned 8,859 common shares, held directly.
Talphera (TLPH) filed a Form 4 disclosing equity grants to a director. On 10/23/2025, the reporting person received 4,267 restricted stock units at $0 and a stock option for 25,600 shares at an exercise price of $1.14. The RSUs and the options each vest 100% on the first anniversary of the grant date, subject to continuous service. Following these transactions, the reporting person held 8,859 shares directly and 25,600 derivative securities (options).
Talphera, Inc. (TLPH) reported an insider equity grant. A director received 4,267 restricted stock units on 10/23/2025, recorded at $0 per unit. Following the grant, the individual directly holds 9,047 shares of common stock.
The director was also granted a stock option for 25,600 shares at an exercise price of $1.14 per share, expiring on 10/22/2035. Both the RSUs and the option are scheduled to vest 100% on the one-year anniversary of the grant date, contingent on continuous service.
Talphera, Inc. (TLPH) reported a director equity grant on a Form 4. The filing shows 4,267 restricted stock units awarded at $0, and a stock option for 25,600 shares with a $1.14 exercise price. Both the RSUs and the option vest 100% on the one-year anniversary of the 10/23/2025 grant date, subject to continuous service. The option expires on 10/22/2035. Following the transaction, the director beneficially owned 8,547 shares of common stock directly.
Talphera (TLPH) reported a director equity grant. On 10/23/2025, the director acquired 4,267 shares of common stock via restricted stock units at $0 and received a stock option covering 25,600 shares at an exercise price of $1.14, expiring 10/22/2035.
The filing states the RSUs vest 100% on the first anniversary of the grant date, subject to continuous service. The option also vests 100% on the one-year anniversary under the same condition. Following the transactions, 17,609 common shares were beneficially owned directly, and 25,600 options were held.
Talphera (TLPH) reported a director equity grant on Form 4 dated 10/23/2025. The filing shows the acquisition of 4,267 shares of common stock at $0, reflecting restricted stock units that each convert into one share and vest 100% on the first anniversary of the grant date.
The director was also granted a stock option for 25,600 shares at an exercise price of $1.14, expiring on 10/22/2035, with 100% vesting on the one-year anniversary of the grant. Following these transactions, the director beneficially owned 7,312 common shares and 25,600 options.
Talphera, Inc. (TLPH) reported a director equity grant on a Form 4. On 10/15/2025, the director received 6,397 restricted stock units at $0 and a stock option for 38,381 shares with a $1.11 exercise price.
Both the RSUs and the option vest in three equal annual installments on October 14, 2026, October 14, 2027, and October 14, 2028, with continuous service required for the option. Following these transactions, the filing lists 6,397 shares of common stock and 38,381 options as directly owned.